A 48-week study involving 644 ALS patients found the drug to be safe and well-tolerated, but the clinical trial did not reach primary or secondary endpoints to prove efficacy, the Cambridge, Mass.-based drugmaker said March 8.
For the next eight weeks, Amylyx said it will communicate with regulatory agencies, experts and the ALS community about whether to remove the treatment from the market. The drugmaker is voluntarily halting promotion of Relyvrio, which the FDA approved in September 2022.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
